Sixty percent of patients with BRAF-mutant melanomas responded to BRAF inhibitor despite a concurrent MEK1 mutation. Theory was tested in single- and double-mutant tumors. CHICAGO — A genetic mutation in MEK1 does not prevent response to BRAF inhibitors...
Filed under: Press Releases, Research, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, meeting, 2012 Annual Meeting, Annual Meeting, AACR Annual Meeting 2012, mutation, Dr. Roger S. Lo, MEK1